PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION



(51) International Patent Classification 5:		(11) luternational Publication Number:	WO 91/04051
	Al	(It) idieranional Edulicados lanmoer:	WO 91/04031
A61K 39/21, C07K 13/00, 7/04	AI	(43) International Publication Date:	4 April 1991 (04.04.91)
(21) International Application Number: PCT/((22) International Filing Date: 19 September 19	US90/053 90 (19.09.5	(75) Inventors/Applicants (for US of [US/US]; 604 Paradise Count (US). KOENIG, Scott [US]	L Gaithersburg, MD 20877
(30) Priority data: 409,596 19 September 1989 (19	9.09.89) t	Rockville, MD 20852 (US). (74) Agents: OLSTEIN, Elliot, M. e Gilfillan, Ceochi & Stewart, 6 land, NJ 07068 (US).	t al., Carella, Bryne, Bain, i Becker Farm Road, Rose-
(60) Parent Application or Grant (63) Related by Continuation US Filed on 19 September 196 (1) Applicants (for all designated States ex MEDIMMUNE, INC. (US/US): 19 Firstfi Gaithersburg, MD 20878 (US). UNITED GOVERNMENT as represented by THE SE OF THE DEPARTMENT OF HEAL HUMAN SERVICES [US/US]; Building 5A50, National Institute of Health, 9000 Pike, Bethesda, MD 20892 (US).	cept US ield Rose STATE CRETAR TH AN 31. Roo	patent), CH (European patent) DK (European patent), ES (is ropean patent), GB (European patent), JP, LU (European patent), SE (Europ	t), DE (European patent)*, European patent), FR (Eu- an patent), IT (European atent), NL (European pa- US. rt. ime limit for amending the
(54) Title: PEPTIDES INCLUDING CTL EPITO	PES OF	IIV PROTEINS AND USE THEREOF	;
(57) Abstract			
Danida for amonto of WTV pertains much us h	av be used	n, GAG protein, and ENV protein, whi to induce or augment cellular immune re	ch include a CTL epitope. sponses against HIV virus
o treat or prevent infection of the animal with HI			
o treat or prevent infection of the animal with HI'			
o treat or prevent infection of the animal with HI'			
o treat or prevent infection of the animal with HI'			·
o treat or prevent infection of the animal with HI		 	·
o treat or prevent infection of the animal with HI			
o treat or prevent infection of the animal with HI		- was	

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filling date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

••	CECIONS Alloca (no 1 0)	es	Spain	MC	Monaco
T	Austria		Finland	MG	Medagascer
Ù	Australia	FT.	-	Ma.	Mali
_	Barbados	FR	France	MR	Meuritania
8		GA	Cabon	WW	Malawi
	Beigium	GB	United Kingdom	NL	Netherlands
	Berkins Faxo	GR	Greats		Norway
C	Bulgaria	HU	Hungsry	МО	
IJ	Benis			PL	Poland
	Brazil	IT	1 taly	RO	Remerki
	Canada	JP	Japan	50	Sudes
CA	Daniel Address Bourbie	KP	Democratic People's Republic	##	Swedon
Œ	Central African Republic		of Korus	===	Sungal
œ	Congo .	KR	Republic of Korea		Seviet Union
CH	Switzerland	ü	Liechtenstein	SU	
CM	Cameroon		Sri Lanks	10	Check
DE	Cormany	LK		TC	Togo
DK	Desmark	w	\$100dmens.j	unt	United States of America

PEPTIDES INCLUDING CTL EPITOPES OF HIV PROTEINS AND USE THEREOF

This invention relates to peptides which include a CTL epitope. The peptides or derivatives thereof may be used to induce and/or augment a CTL response. More particularly, this invention relates to HIV (Human Immunodeficiency Virus) proteins and peptide fragments which include CTL epitopes, and which may be used to induce a CTL response to HIV virus.

Cell-mediated immunity (or CMI) of virus infections is thought to be a major line of host defense against viral infections. CMI may be significant in the development of an effective vaccine against human immunodeficiency virus (HIV), or AIDS virus because HIV vaccines and/or therapies based on the generation of passive transfer of HIV-specific antibody in the absence of cell-mediated immunity have not yielded consistent protection in primates challenged with the HIV virus. Thus, interest has turned to the induction of cell-mediated immune responses to HIV and to the identification of specific epitopes of HIV proteins that stimulate a cytotoxic I lymphocyte, (or CTL) response.

1.19

In accordance with an aspect of the present invention, there is provdied a peptide fragment which includes an epitope which is recognized by cytotoxic T lymphocytes (CTL) induced by an HIV protein or CTL epitope thereof. The HIV protein is preferably an HIV-1 protein.

In a preferred aspect, the peptide fragment is recognized by CTL induced by the NEF, GAG, or ENV protein, or a CTL epitope thereof.

The term "peptide fragment" as used herein means a peptide having a number of amino acid residues less than the number of amino acid residues present in the native protein which includes the CTL epitope.

A peptide fragment which includes an epitope which is recognized by CTL induced by an HIV protein is sometimes herein referred to as a peptide fragment containing a CTL epitope.

The peptide fragment may be a fragment of the native protein or an analogue or derivative thereof, provided that such peptide fragment is recognized by CTL induced by the native protein or CTL epitope of such native protein.

The peptide fragment may be comprised of only the amino acid residues which form the CTL epitope, or it may include additional amino acid residues; however, as hereinabove noted, the fragment contains less amino acid residues than the native protein.

In accordance with one embodiment, there is provided a peptide fragment which includes an epitope which is recognized by CTL induced by the NEF protein of HIV-1 (hereinafter sometimes referred to as NEF protein). The peptide fragment which includes a CTL epitope which is recognized by CTL induced by NEF protein may be a fragment of the NEF protein containing such a CTL epitope or an analogue or

derivative thereof. The CTL epitope of the NEF protein is contained in amino acid residues 73 to 97 of NEF protein according to the Los Alamos, National Laboratory HIV sequence data base as follows (single letter amino acid code)

QVPLRPMT(Y or F, preferably Y)KAAVDLSHFLKEKGGL, and more particularly, such CTL is comprised of residues 73 to 82 (Los Alamos sequence), which have the following structure as defined by the single letter amino acid code:

QVPLRPMT(Y or F, preferably Y)K.

In accordance with another embodiment, there is provided a peptide fragment which includes an epitope which is recognized by CTL induced by the GAG protein of HTV-1 or CTL epitope thereof (sometimes hereinafter referred to as GAG protein). The peptide fragment which includes a CTL epitope which is recognized by CTL induced by GAG protein may be a fragment of the GAG protein containing such a CTL epitope or an analogue or derivative thereof. The CTL epitope of the GAG protein is contained in amino acid residues 179 to 193 of the GAG protein, which has the following structure as defined by the single letter amino acid code:

ATPQDLN(T or M, preferably T)MLN(T or I, preferably T)VGG.

In accordance with yet another embodiment, there is provided a peptide fragment which includes an epitope which is recognized by CTL induced by the ENV protein of HIV-1 or CTL epitope thereof (sometimes hereinafter referred to as ENV protein). The peptide fragment which includes a CTL epitope which is recognized by CTL induced by ENV protein may be a fragment of the ENV protein containing such a CTL epitope or an analogue or derivative thereof. The

CTL epitope of the ENV protein is contained in amino acid residues 566 to 590 of the ENV protein, which has the following structure as defined by the single letter amino acid code:

LQLTVWGIKQLLAR(I or V, preferably I)LAVERYL(K or R, preferably K)DQ.

In accordance with a further embodiment, there is provided a peptide fragment which includes another epitope which is recognized by CTL induced by the ENV protein of HIV-1 or a CTL epitope thereof. This CTL epitope of the ENV protein is contained in amino acid residues 54 to 80 of the ENV protein, which has the following structure as defined by the letter amino acide code:

CAS (D or E, preferably D)A(K or R, preferably K)(A or S, preferably A)Y(D,S,K, or E, preferably D)(T,K, or P, preferably T)E(V,A,S, or K, preferably V)HN(V or I, preferably V)WA(T or K, preferably T)(H or Q, preferably H)ACVP(T or S, preferably T)(D or N, preferably D)P(N or S, preferably N).

The peptides hereinabove described may be produced by known techniques and obtained in substantially pure form. For example, the peptides may be synthesized on an automatic synthesizer.

Journal of the American Chemical Society, Vol. 85, pages 2149-54 (1963). It is also possible to produce such peptides by genetic engineering techniques. The peptide may also be produced by chemical or enzymatic buildup from smaller peptide fragments, or by cleavage of larger peptides or proteins or by solution phase peptide synthesis.

In accordance with another aspect of the present invention, a peptide fragment which includes an epitope, which is recognized by CTL induced by an HIV protein, may be employed in an assay for determining

HIV infection. More particularly, the assay comprises contacting cells coated with a peptide fragment including a CTL epitope, which is recognized by CTL induced by a HIV protein, with lymphocytes from the animal, and determining lysis of the cells to indicate infection of the animal with HIV. The cells coated with peptide are either autologous cells or an in vitro cell line compatible with the HLA type (MHC allele(s)) of the animal being tested. The peptide fragment containing a CTL epitope may be a peptide fragment of the NEF protein, or a peptide fragment of the GAG protein, or a peptide fragment of the ENV protein or analogs or derivatives thereof as hereinabove described, or mixtures thereof. In general, such an assay is effective for testing an individual of a particular HLA type for CMI responses to said peptide fragments.

In one embodiment, B-cells from the animal are coated with a peptide fragment having a CTL epitope of an HIV protein as hereinabove described. B-cells may include a detectable label or marker, such as a radioactive chromium marker. The B-cells are then contacted with peripheral blood lymphocytes (or PBL) from the animal. If the peripheral blood lymphocytes contain CTL induced by an HIV protein containing the CTL epitope of the peptide fragment, the CTL will recognize the CTL epitope of the peptide fragment coating the B-cells, and will lyse the B-cells. Lysis of the B-cells will be indicated by release of the detectable marker into the assay medium. If there is lysis of the B-cells as indicated by release of the detectable marker into the medium, then the peripheral blood lymphocytes contain CTL induced by an HIV protein and the animal is infected with HIV.

In accordance with yet another aspect of the present invention, there is provided a process for augmenting a CTL response which comprises contacting peripheral blood lymphocytes from an animal infected with HIV with a peptide fragment(s) including a CTL epitope as hereinabove described. The peptide fragment preferably contains a CTL epitope of the NEF protein, or a CTL epitope of the GAG protein, or a CTL epitope of the ENV protein. The CTL response may be induced in vitro. The CTL response may be augmented in vitro by incubating peripheral blood mononuclear cells (PBMC's) from seropositive individuals with a peptide of the type hereinabove described.

The peripheral blood lymphocytes having augmented CTL may then be used to treat the animal. For example, PBL augmented in CTL may be administered intravenously as an appropriate physiological suspension (for example in PBS) containing from 10^5 to 10^{10} cells.

In accordance with another aspect, CTL may be induced in vivo by administering to an animal infected with HIV a peptide fragment having a CTL epitope of the type hereinabove described. More particularly, CTL will be induced in vivo by immunization with constructs that contain CTL sites against HIV that have been described above (E.g. Nef7). These vaccines can be formulated using standard techniques with carriers and/or adjuvants (for example, alum, bacterial cell wall components, vegetable oil formulations or derivatives thereof, etc.) to induce CTL responses. In addition, a peptide or peptide derivative having a CTL epitope can be synthesized and/or chemically modified to contain exogenous amino acids and/or fatty acid or

WO 91/04051

hydrophobic moieties necessary for induction and/or augmentation of a CTL response. An example of a method of modifying a peptide or peptide derivative having a CTL epitope is described in Deres, et al, Nature, Vol. 342, November 30, 1989, pgs. 561-564. The dosage and administration protocol can be optimized in accordance with standard vaccination practices. A useful dosage for an average adult can be in the range of 1.0 to 1500 micrograms.

The invention will now be described with respect to the following examples; however, the scope of the invention is not to be limited thereby.

EXAMPLE I

(a) Recombinant vaccinia virus construction. The nef coding sequence was obtained from Dr. Venkatesan, Laboratory of Medical Microbiology, NIAID, NIH, as a cDNA clone. The cDNA was derived from the HIV isolate, NL432 (Adachl et a. (1986) J. Virol. 59, 284). Using standard recombinant DNA technique, the nef gene was excised and placed into a vaccinia virus integration vector. The integration vector contains a vaccinia virus promoter termed P 7.5. Promoter P 7.5 allows expression of foreign genes at early and late times after infection. The nef coding sequence was placed downstream of p 7.5. The P 7.5 nef casette was inserted into the thymidine kinase (TK) locus of vaccinia virus by standard procedures resulting in insertional inactivation of TK. A TK-recombinant vaccinia virus, designated vTFnef, was isolated and purified. Expression studies were performed with vTFnef to confirm proper expression of Nef. Cell monolayers were infected with vTFnef in the presence of radiolabeled amino acids or myristic acid. Cell lysates were

immunoprecipitated with Nef anti-serum. A specific 27 kd protein was precipitated. The 27 kd protein corresponds to the predicted molecular size as well as previously reported values for Nef (J.S. Allan et al., Science (1985) 230. 810; G. Franchini et al., Virology (1986) 155, 593). Nef is also myristoylated demonstrating authentic expression of the nef coding sequence.

(b) Identification of individuals with Nef-specific CTL responses. Recombinant virus, vTFnef. was used to screen circulating T lymphocytes for CTL activity directed to Nef from a group of 12 healthy, HIV-1 seropositive HIV-1 patients. Fresh peripheral blood mononuclear cells (PBMC) were obtained from these patients and tested for cytolytic activity against autologous cells infected with vTFnef. Unfractionated PBMC were separated over Hypaque/Ficoll, resuspended in RPMI-1640 medium (M.A. Bioproducts, Walkersville, MD) with 10% fetal calf serum, and assayed on the day of separation as described previously (Koenig et al. (1988) Proc. Natl. Acad. Sci USA 85, 8638-8642). Autologous cells were prepared from B lymphocytes obtained from the same patient tested for CTL activity, i.e. to match HLA types for both target and effector cells. Autologous B lymphoblastoid cell lines from these HIV seropositive patients were prepared by transformation wtih 'Epstein-Barr Virus (EBV) as described previously (Blumberg et al. (1987) J. Infect. Dis. 155, 877; Koenig et al. (1988) Proc. Natl. Acad. Sci USA 85, 8638-8642). These cell lines were used as targets in an autologous chromium-release assay as described by Koenig, et al. (ibid). In this assay, lysis of labeled target cells results in the release of chromium into the medium. Freshly isolated

PCT/US90/05343

autologous PBMC were used as effector cells in the assay. Two subjects had a Nef-specific cytotoxic response that was approximately five-fold higher than that observed for control vaccinia virus infected target cells.

(c) Mapping a Nef-specific CTL epitope. NEf-specific CTL response of these two donors was further examined by testing a set of peptides individually that spanned the entire Nef protein sequence. Sixteen peptides covering the nef region were synthesized in overlapping linear sequences, 25 residues in length with 13 residue overlaps. The peptides were produced as described in part (d) below. Autologous cells were pulsed with 25 to 50 uM peptide for 12 hours before labeling with Cr-51. Chromium-release assays were performed as described (Koenig et al., op. cit.). One peptide was recognized as a CTL target. This peptide, designated Nef7, corresponds to Nef amino acid residues 73 to 97 according to the Los Alamos National Laboratory HIV sequence database. The N- and C-terminal boundaries of this epitope were fine-mapped by peptide deletions (A summary of peptides used for fine-mapping is shown in Table 1). A 10 residue peptide (10-mer), Nef7B, corresponding to residues 73 to 82 (QVPLRPMTYK), was capable of serving as the CTL epitope with the same reactivity as Nef7 (25-mer).

Individuals tested exhibiting Nef CTL activity are designated #1 and #2. Peptide NEf7B is contained within a highly conserved region of the Nef protein sequence (at least 90 percent conserved in all HIV-1 isolates sequenced to date). Although these subjects were classified as seropositive by standard screening assays; detection of antibody responses to Nef was negative by radioimmunoassay.

(d) <u>Peptide synthesis</u>. Synthetic peptides were constructed using the stepwise solid phase approach of Merrifield (J. Am. Chem. Soc. (1963) 85, 2149) on an Applied Biosystems Model 430A peptide synthesizer. All synthetic peptides were assembled on an insoluble copolymer "PAM" resin consisting of styrene and divinylbenzene.

The symmetric anhydride derivatives were used as the acylating species for all amino acids except asparagine, glutamine, arginine and histidine. These four amino acids were coupled as the 1-hydroxybenzotriazole esters. The reactive side chains of amino acids were protected during the synthesis. The protecting groups used were 0-benzyl for Asp and Glu; benzyl for Ser and Thr; p-methylbenzyl group for Cys; tosyl for Arg; dinitrophenyl for His; 2-chlorobenzyloxycarbonyl for Lys; 2-bromobenzyloxycarbonyl for Tyr; and formyl for Trp.

Following their syntheses, peptides were cleaved with anhydrous liquid HF in the presence of anisole, dimethlysulfide and ethanedithiol. Once cleaved the peptides were precipitated in ether, and then extracted from the resin with 30% (v/v)glacial acetic acid in water.

The cleaved peptides from the resin were analyzed and subsequently purified to greater than 95% homogeneity, using a Vydac C-4 reverse-phase column, and Beckman "System Gold" HPLC. The correct amino acid content of each peptide was verified by hydrolyzing purified material with constant boiling in 6N HCl at 150 degrees centigrade for 2 hours. Once hydrolyzed, these samples were then subject to amino acid compositional analysis using the Beckman "System Gold" amino acid analyzer.

- (e) <u>CTL assay</u>. Preparation of PBMCs, generation of autologous lymphoblastoid cell lines and cytotoxicity microassays (CTL) were done as described in part (b) above except that the autologous B lymphoblastoid cell line was coated with the Nef7 peptide instead of being infected with the noted viral vector.
 - (f) Augmenting CTL production in vitro. A protocol which was used for boosting (augmenting) CTLs in vitro is described as follows. Fresh PBMCs from seropositive individuals were separated over Hypaque/Ficoll, resuspended in RPMI-1640 medium containing 10% human serum and 10 ug/ml of Nef7 peptide and incubated for 3 days. After 3 days, cultures were supplemented with recombinant IL-2 at 5 units/ml. At day 5, cultures were restimulated with fresh PMBC pulsed with Nef7 peptide for 3 hours, irradiated with 3000 rads, and washed to remove excess peptide. Cells were restimulated as before on day 14.

-12-

Table 1

Overlapping Peptides	Positions
QEEEEVGFPVTPQVPLRPMTYKAAV	(61-85)
QVPLRPMTYKAAVDLSHFLKEKGGL	(73-97)
FPVTPQVPLRPMTYKAAVDLS	(68-88)
QVPLRPMTYKAAVDLS	(73-88)
QVPLRPMTYK	(73-82)
VPLRPMTYK	(74-82)
PLRPMTYK	(75-82)
LRPMTYK	(76-82)
QVPLRPMTY CONTROL OF THE PROPERTY OF THE PROPE	(73-81)
QVPLRPMT	(73-80)
QVPLRPMTFK	(73-82)
PMTYKAAVDLSHFLKEKGGL	(78-97)
AAVDLSHFLKEKGGL	(83-97)
SHFLKEKGGL	(88-97)

The term "animal" as used herein includes humans and non-humans and is preferably a human. It is to be understood, however, that the scope of the present invention is not to be limited to the specific embodiments described above. The invention may be practiced other than as particularly described, and within the scope of the accompanying claims, numerous modifications may be made of the specific teachings contained herein.

WHAT IS CLAIMED IS

- 1. A peptide fragment which includes an epitope which is recognized by CTL induced by one of NEF protein, GAG protein, or ENV protein, or a CTL epitope of such proteins.
- 2. The peptide fragment of Claim 1 wherein the peptide fragment includes an epitope which is recognized by CTL induced by NEF protein or a CTL epitope thereof.
- 3. The peptide fragment of Claim 2 wherein the peptide fragment includes a CTL epitope of NEF protein.
- 4. The peptide fragment of Claim 3 wherein the peptide fragment is comprised of amino acid residues 73 to 97 of NEF protein.
- 5. The peptide fragment of Claim 3 wherein the peptide fragment is comprised of amino acid residues 73 to 82 of NEF protein, as defined by the single letter amino acid code:

QVPLRPMT(Y or F)K.

6. The peptide fragment of Claim 5 wherein the peptide fragment has the following structural formula:

OVPLRPMTYK.

- 7. The peptide fragment of Claim 1 wherein the peptide fragment includes an epitope which is recognized by CTL induced by GAG protein or a CTL epitope thereof.
- 8. The peptide fragment of Claim 7 wherein the peptide fragment includes a CTL epitope of GAG protein.
- 9. The peptide fragment of Claim 8 wherein the peptide fragment is comprised of amino acid residues

179 to 193 of GAG protein, as defined by the single letter amino acid code:

ATPQDLN(Tor M)MLN(T or I)VGG.

10. The peptide fragment of Claim 9 wherein the peptide fragment has the following structural formula:

ATPQDLNTMLNTVGG

- 11. The peptide fragment of Claim 1 wherein the peptide fragment includes an epitope which is recognized by CTL induced by ENV protein or a CTL epitope thereof.
- 12. The peptide fragment of Claim 11 wherein the peptide fragment includes a CTL epitope of ENV protein.
- 13. The peptide fragment of Claim 12 wherein the peptide fragment is comprised of amino acid residues 566 to 590 of ENV protein, as defined by the single letter amino acid code:

LQLTVWGIKQLLAR(I or V)LAVERYL(K or R)DQ.

14. The peptide fragment of Claim 13 wherein the peptide fragment has the following structural formula:

LQLTVWGIKQLLARILAVERYLKDQ.

15. The peptide fragment of Claim 12 wherein the peptide fragment is comprised of amino acid residues 54 to 80 of ENV protein, as defined by the single letter amino acid code:

CAS(D or E)A(K or R)(A or S)Y(D,S,K, or E)(T,K, or P)E(V,A,S, or K)HN (V or I)WA(T or K)(H or Q)ACVP(T or S)(D or N)P(N or S).

16. The peptide fragment of Claim 15 wherein the peptide fragment has the following structural formula:

CASDAKAYDTEVHNVWATHACVPTDPN.

PCT/US90/05343

17. An assay for determining infection of an animal with HIV virus, comprising:

contacting cells from the animal coated with the peptide fragment of Claim 1 with peripheral blood lymphocytes from said animal, said cells being autologous cells or cells compatible with the HLA type of the animal being tested; and

determining lysis of said cells to indicate infection of said animal with HIV virus.

18. An assay for determining infection of an animal with HIV virus, comprising:

contacting cells coated with the peptide fragment of Claim 4 with peripheral blood lymphocytes from said animal, said cells being autologous cells or cells compatible with the HLA type of the animal being tested; and

determining lysis of said cells to indicate infection of said animal with HIV virus.

19. An assay for determining infection of an animal with HIV virus, comprising:

contacting cells from the animal coated with the peptide fragment of Claim 5 with peripheral blood lymphocytes from said animal, said cells being autologous cells or cells compatible with the HLA type of the animal being tested; and

determining lysis of said cells to indicate infection of said animal with HIV virus.

20. A process for augmenting a CTL response, comprising:

contacting peripheral blood lymphocytes from an animal infected with HIV with the peptide fragment of Claim 1.

21. A process for augmenting a CTL response, comprising:

contacting peripheral blood lymphocytes from an animal infected with HIV with the peptide fragment of Claim 4.

22. A process for augmenting a CTL response, comprising:

contacting peripheral blood lymphocytes from an animal infected with HIV with the peptide fragment of Claim 5.

- 23. The process of Claim 20 wherein said CTL response is augmented by systemically administering said peptide fragment to an animal infected with HIV.
- 24. A process for inducing a CTL response, comprising:

administering to an animal infected with HIV the peptide fragment of Claim 1.

25. A process for inducing a CTL response, comprising:

administering to an animal infected with HIV the peptide fragment of Claim 4.

26. A process for inducing a CTL response, comprising:

administering to an animal infected with HIV the peptide fragment of Claim 5.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US90/05343

Journal of Immunology, volume 145, No. 1, issued 01 July 1990. Koenig et al "Mapping The Fine Specificity Of A Cytolytic T Cell Response To HIV-1 nef Protein", pages 129-135. European Journal of Immunology, Volume 19, issued 1989. Culmann et al., "An antigenic peptide of the HIV-1 NEF Protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA-B molecules", pages 2383-2386. see entire document. In Journal of Experimental Medicine, Volume 170, issued December 1989. Takahashi et al. "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immuno- deficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. *Secument defining the general state of the attraction is not considered to be of lancinguar reference causes active the careful recognition of an immunodominant in the anticular reference the consument of the morning of the consument and the protection of the consument and the protection of the consument and the protection of the consument of the consument and the protection of the consument of the cons	I, CLASS	IFICATIO	N OF SUBJECT MATTER (if several classe	fication symbols apply, indicate all) 4	
U.S. Minimum Documentation Searched	According	te Internet	onal Patent Classification (IPC) or to both Nat	ional Classification and IPC	
U.S. Classification System S30/300, 328; 435/4; 424/89 U.S. Decumentation Searched either than Minimum Decumentation to the Effort that such Decuments are included in the Fields Searched 4 Databases: Dialog (Files 157,72,73,399.155,154,5) Automated Patent System (File USPAT, 1971-1990) M. DOCUMENTS COMSIDERED TO SE RELEVANT * Category Classion al Decument, 1 with indication, where approximate, of the relevant seasages ** T. Journal of Timmunology, volume 145, 1-26 T. Journal of Timmunology, volume 145, 1-26 A Cyttolytic T Cell Response To HIV-1 nef Protein*, pages 129-135. X. European Journal of Immunology, 1-26 Wolume 19, issued 1989, Culmann et al., "An antigenic peptide of the HTV-1 NEF Protein recognized by Cytotoxic T lymphocytes of seropositive individuals in association with different HLA-R molecules*, pages 2383-2386, see entire document. I.P. The Journal of Experimental Medicine, 1-26 Takehashi et al. "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immunodeficiency virus envelope protein*, pages 2023-2035, especially pages 2023 & 2026. *Secund Categories of case decuments: ** **Secund Categories of the secundary of the pathents of the categories of the invasorial state o	IPC(5):	A61K 3	9/21: CO7K 13/00; CO7K 7/0)4	
Minimum Documentation Searched	LS. CT.	.: 530	/300. 328: 435/4; 424/89		
U.S. Decumentation System Classification Symbols 530/300, 328; 435/4; 424/89 U.S. Decumentation Searched either than Minimum Decumentation to the Extent Inch such Decuments are Included in the Profess Searched • Databases: Dialog (Files 157,72,73,399.155,154,5) Automated Patent System (File USPAT, 1971–1990) III. DOCUMENTS CONSIDERED TO SE RELEVANT* To Journal of Immunology, volume 145, volume 146, issued 01 July 1990. Koening et al., "Mapping The File Specificity Of A Cytolytic T Cell Response To HIV-1 nef Protein", pages 129–135. I European Journal of Immunology, volume at al., "An antigenic peptide of the HIV-1 NEF Protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA-8 molecules", pages 2383–2386, see entire document. I,P Volume 170, issued December 1989, Takahashi et al., "Structure Requirements for class I MKC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunoded antigen presentation and cytotoxic T cell recognition of an immunoded cetter in the Nolecule-medicated antigen presentation and cytotoxic T cell recognition of an immunoded cetter in cells of the luman immunoded cetter i					
Classification System U.S. Documentation Searched either than Minimum Documentation to the Extent Intel such Documents are Included in the Paties Searched ** Databases: Dialog (Files 157.72.73.399.155.154.5) Automated Patent System (File USPAT. 1971-1990) III. DOCUMENTS CONSIDERED TO BE RELEVANT ** The Considered Patent System (File USPAT. 1971-1990) III. DOCUMENTS CONSIDERED TO BE RELEVANT ** The Considered Patent System (File USPAT. 1971-1990) III. DOCUMENTS CONSIDERED TO BE RELEVANT ** The Journal of Immunology, volume 145,				Intion Searched !	
Documentation Searched either than Minimum Documentation to the Extent that such Documents are Included in the Radda Searched 4 Databases: Dialog (Files 157.72.73.399.155.154.5) Automated Patent System (File USPAT. 1971-1990) III. DOCUMENTS COMSIDERED TO BE RELEVANT* Catalon of Document, "web melazion, where appropriate, of the reservant passages if Relevant to Claim." Napping The File Specificity Of A Cytolytic T Cell Response TO HIV-1 nef Protein", pages 129-135. I European Journal of Immunology, Volume 19, issued 1989, Culmann et al., "An antigenic peptide of the HIV-1 NEF Protein recognized by Cytotoxic T lymphocytes of seropositive individuals in association with different HLA-8 molecules", pages 2383-2386, see entire document. I,P The Journal of Experimental Medicine, Volume 170, issued December 1989. Takahashi et al. "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immunodeficiency virus envelope protein", pages 2023 & 2026. *Secular Laterports of cased decument: " **Secular Categories of Later Control of Comment Offician Comment Com	Classification	n System			
Decumentation Searched either than Minimum Decumentation to the Electric that such Decuments are Included in the Fledda Searched 4 Databases: Dialog (Files 157,72,73,399.155,154,5) Automated Patent System (File USPAT, 1971-1990) III. DOCUMENTS CONSIDERED TO BE RELEVANT* III. DOCUMENTS CONSIDERED TO BE RELEVANT* III. DOCUMENTS CONSIDERED TO BE RELEVANT* III. Journal of Immunology, volume 145, No. 1, issued 01 July 1990. Koenig et al "Mapping The Fine Specificity Of A Cytolytic T Cell Response To HIV-1 nef Protein", pages 129-135. III. European Journal of Immunology, volume 19, issued 1989, Culmann et al., "An antigenic peptide of the HIV-1 NEF Protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA-8 molecules", pages 2383-2386, see entire document. I.P. The Journal of Experimental Medicine, volume 170, issued December 1989, Takahashi et al. "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunod deficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. *Secule Categories of cased decument: " **Secule Categories of cased decument: " **Secule Categories of cased decument: " **Seculed Categories of a series of secule relation of the means and decisions on soft secules of comment to co					
Decumentation Searched either than Minimum Decumentation to the Extent that such Documents are included in the Ruids Searched 4 Databases: Dialog (Files 157,72,73,399,155,154,5) Automated Patent System (File USPAT, 1971-1990) III. DOCUMENTS COMSIDERED TO BE RELEVANT* Category* Citation of Document, " units include the superconnic, of the relevant messages if Relevant to Claim. T			530/300, 328; 435/4	; 424/89	
Databases: Dialog (Files 157,72,73,399,155,154,5) Automated Patent System (File USPAT, 1971-1990) M. DOCUMENTS CONSIDERED TO SE RELEVANT * Integrated To Control of Decement, "with melicibles, where appropriate, of the relevant messanges of the relation of the relevant messanges of the relation of the re	U.S.				
Databases: Dialog (Files 157,72,73,399,155,154,5) Automated Patent System (File USPAT, 1971-1990) M. DOCUMENTS CONSIDERED TO SE RELEVANT * Import			_		
Databases: Dialog (Files 157,72,73,399,155,154,5) Automated Patent System (File USPAT, 1971-1990) III. DOCUMENTS COMSIDERED TO SE RELEVANT* Interpretable of Citation of Document, "well medication, where appropriate, of the reference passages II Reference to Claim. Tournal of Immunology, volume 145, No. 1, issued 01 July 1990. Koenig et al. "Mapping The Fine Specificity Of A Cytolytic T Cell Response To HIV-1 nef Protein", pages 129-135. X European Journal of Immunology, Volume 19, issued 1989, Culmann et al., "An antigenic peptide of the HTV-1 XEP Protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA-R molecules", pages 2383-2386, see entire document. I,P The Journal of Experimental Medicine, Volume 170, issued December 1989, Takahashi et al. "Structure Requirements for class I NHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immuno- deficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. *Special Categories of seed documents: " "A decembed Officine the general state of line and which is not considered to be of particular relevance To eacher occurrent but absoluted on a relevance in the second of cannot be considered in the constance of the					
M. DOCUMENTS CONSIDERED TO SE RELEVANT * Category			to the Extent that such Documents	are included in the Fields Searched 6	
Automated Patent System (File USPAT. 19/1-1990) III. DOCUMENTS CONSIDERED TO SE RELEVANT 6 Category * Citation of Document. " with indication, where appropriate, of the relevant passages III Relevant to Claim." T	D	D	-1 (Files 157 72 73 309	155.154.5)	
Totalion at Document, "I with medication, where approximate, of the referent passages of the provided to the state of the referent passages of the provided to the state of the referent passages of the provided to the referent passages of the provided to the referent passages of the provided to the provided to the referent passages of the provided to the provided t	vacabas	ses: D	Laiog (Files 157,72,757575	971-1990)	
Journal of Immunology, volume 145, No. 1, issued 01 July 1990. Koenig et al "Mapping The Fine Specificity Of A Cytolytic T Cell Response To HIV-1 nef Protein", pages 129-135. European Journal of Immunology, Volume 19, issued 1989, Culmann et al., "An antigenic peptide of the HIV-1 NEF Protein recognized by Cytotoxic T lymphocytes of seropositive individuals in association with different HLA-8 molecules", pages 2383-2386, see entire document. Ine Journal of Experimental Medicine, Volume 170, issued December 1989. Takahashi et al. "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immuno- deficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. *Special categories of cased documents: " **Special categories of cased documents: " ***Special categories of	Automat	ted rai	ent System (File OSIRI, 1	,,,, 1,,,,,,	
Journal of Immunology, volume 145, No. 1, issued 01 July 1990. Koenig et al "Mapping The Fine Specificity Of A Cytolytic T Cell Response To HIV-1 nef Protein", pages 129-135. European Journal of Immunology, Volume 19, issued 1989, Culmann et al., "An antigenic peptide of the HIV-1 NEF Protein recognized by Cytotoxic T lymphocytes of seropositive individuals in association with different HLA-8 molecules", pages 2383-2386, see entire document. Ine Journal of Experimental Medicine, Volume 170, issued December 1989. Takahashi et al. "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immuno- deficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. *Special categories of cased documents: " **Special categories of cased documents: " ***Special categories of	III DOCIN	HENTS C	OMERGED TO SE RELEVANT		
Journal of Immunology, volume 145, No. 1, issued 01 July 1990. Koenig et al "Mapping The Fine Specificity Of A Cytolytic T Cell Response To HIV-1 nef Protein", pages 129-135. European Journal of Immunology, Volume 19. issued 1989. Culmann et al., "An antigenic peptide of the HIV-1 NEF Protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA-8 molecules", pages 2383-2386, see entire document. I,P The Journal of Experimental Medicine, Volume 170, issued December 1989. Takahashi et al. "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immuno- deficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. *Special Enterports of Ended documents: " "A decument defining the general state of internal materials and the gate "I decument mount may be the consumence of the particular retembers to be definited in the model. All the pages and the consumered retembers and the consumered in the distribution of the consumeration of the antimother and the model of the particular retembers to the consumeration of the particular retembers to the consumeration of the particular retembers to the consumeration of the consumeration of the particular retembers to the consumeration of the model and model an				roomate, of the relevant sessees 12	Relevent to Claim No. 13
No. 1, issued 01 July 1990. Koenig et al "Mapping The Fine Specificity Of A Cytolytic T Cell Response To HIV-1 nef Protein", pages 129-135. European Journal of Immunology, Volume 19, issued 1989. Culmann et al., "An antigenic peptide of the HTV-1 NEF Protein recognized by Cytotoxic T lymphocytes of seropositive individuals in association with different HLA-B molecules", pages 2383-2386, see entire document. The Journal of Experimental Medicine, Volume 170, issued December 1989. Takahashi et al. "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immunodeficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. *Secund categories of cased documents: " *Secund categories of cased docum	- Stedony				
et al "Mapping The Fine Specificity Of A Cytolytic T Cell Response To HIV-1 nef Protein", pages 129-135. European Journal of Immunology, Volume 19, issued 1989. Culmann et al., "An antigenic peptide of the HIV-1 NEF Protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA-B molecules", pages 2383-2386. see entire document. The Journal of Experimental Medicine, Volume 170, issued December 1989. Takahashi et al. "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immuno- deficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. *Secul categories of case documents: "	ті	001	TENSI OF IMMUNOTOGY, V	100 Coopie	1 20
The Journal of Experimental Medicine, 1-26 Tolume 170, issued December 1989. Takahashi et al. "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunod determinant of the human immunodeficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. *Special categories of cited decuments: " **Special categories of cited deciments: " **Special categories o	-	.\0.	1, issued of duly is	o Checificity	
European Journal of Immunology, Volume 19, issued 1989, Culmann et al., "An antigenic peptide of the HTV-1 NEF Protein recognized by Cytotoxic T lymphocytes of seropositive individuals in association with different HLA-B molecules", pages 2383-2386, see entire document. The Journal of Experimental Medicine, Volume 170, issued December 1989. Takahashi et al. "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immuno- deficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. *Special categorys of cases documents: " **A- decument defining the general state of the art which is not considered to be of particular relevances or their which is not considered to be of particular relevances or the claimed in the constitution of the consideration of the consideration of the consideration of the particular relevances: the claimed in the consideration nevel or cannot be considerated nevel or cannot be considerated in which is not considerated in the consideration of the particular relevances: the claimed interest an invention of the consideration of the consideration of the consideration of the consideration of the page of the	- 1	9.0	ar., "Mapping the fit	enonge To	1
The Journal of Experimental Medicine, Takahashi et al., "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immunodeficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. **Special categories of cited decuments: "I the decument deficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. **Special categories of cited decuments: "I the decument defining the general state of the attained and the categories and the published on or after the international films gate **Special categories of cited decuments: "I the decument deciment but published on or after the international films gate **Special categories of cited decuments: "I the decument deciment deciment but published on or after the international films gate **Special categories of cited decuments: "I the decument deciment deciment but published on or after the international films gate **Special categories of cited decuments: "I the decument deciment decument but published on or after the international films of province accument but published on or after the international films of province accument but published on or after the international films of province accument but published on or after the international films of province accument but published and or after the international films of province accument but published or an order of antivologies or an order of accument order		Of	A CYCOLYTIC I Cell Ke	.e 29_1 3 K	
Volume 19, issued 1989. Culmann et al., "An antigenic peptide of the HTV-1 NEF Protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA-8 molecules", pages 2383-2386, see entire document. The Journal of Experimental Medicine, Volume 170, issued December 1989. Takahashi et al. "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immuno- deficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. *Special categories of cased documents: " *Special categories of cased of cased companies of cased of case of cased of c	1	H L/	-1 <u>uer</u> proceru , bada	:a 147-144	1
Volume 19, issued 1989. Culmann et al., "An antigenic peptide of the HTV-1 NEF Protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA-8 molecules", pages 2383-2386, see entire document. The Journal of Experimental Medicine, Volume 170, issued December 1989. Takahashi et al. "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immuno- deficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. *Special categories of cased documents: " *Special categories of cased of cased companies of cased of case of cased of c	1		Ye	mology:	1-26
"An antigenic peptide of the HTV-1 NEF Protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA-8 molecules", pages 2383-2386, see entire document. The Journal of Experimental Medicine, Volume 170, issued December 1989, Takahashi et al. "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immuno- deficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. *Secund categories of cased documents: " "A" document defining the general state of the art which is not considered to the published one of the the decimant of the considered to the considered to the virus decimal means the principle of theory underly intensity and case of the decimant of the considered to intensity steel and case the considered to involve an invention streament of satisfaction of the considered to involve an invention streament in the antiferring to an eval decision, use, exhibition or other means. To document referring to an eval decision, use, exhibition or other means. The document published prior to the international hims date but	x 1	Eur	copean Journal of Immu	Chimana se si	1 -20
HIV-1 NEF Protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA-B molecules", pages 2383-2386, see entire document. The Journal of Experimental Medicine, 1-26 Volume 170, issued December 1989. Takahashi et al. "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immuno-deficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. *Special categories of cated documents: " "A decument defining the general state of the art which is not carefuled to define and not in careful with the application of the decument defining the general state of the international films of the definition of the international films of the definition of the international films of the definition of the decument defining the general state of the art which is not careful to define definition of the international films of the definition of the international films of the decument with the application of the decument which may throw doubts on priority claimed or which is crime to established after the international films of the decument with the application of the internation of the i	-				
cytotoxic T lymphocytes of seropositive individuals in association with different HLA-R molecules", pages 2383-2386, see entire document. The Journal of Experimental Medicine, Volume 170, issued December 1989. Takahashi et al. "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immuno-deficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. *Special categories of cited documents: ** "A" decument defining the general state of the art which is not cases and the deficiency virus envelope protein", pages 2023 & 2026. *Truster decument auditable after the international film or priority date and not in candical with the application of the companied to the or priority date and not in candical with the application of the companied to the or priority date and not in candical with the application of the set of the companied to the priority date and not in candical with the application of the set of the companied of the priority date and not in candical with the application of the set of the priority date and not in candical with the application of the set of the priority date and not in candical with the application of the set of the priority date and not in candical with the application of the priority date and not in candical with the application of the priority date and not in candical with the application of the priority date and not in candical with the application of the priority date and not in candical with the application of the priority date and not in candical with the application of the priority date and not in candical with the application of the priority date and not in candical with the application of the priority date and not in candical with the application of the priority date and not in candical with the application of the priority date and not in candical with the application of the priority date and not in candical with the application of the priority date and not in candical with the application of the p	- 1	"Ar	antigenic peptide of	tne	į.
individuals in association with different HLA-B molecules", pages 2383-2386, see entire document. The Journal of Experimental Medicine, Volume 170, issued December 1989. Takahashi et al. "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immunodeficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. *Special categories of cated documents: " "A" document document but published on or after the international films of stricture relevance in the anticular relevance which is not cannot be considered in the published after the international films of priority date and not in confinct with the application of the common document but published on or after the international films of anioner cannot be considered in evidence: the claimed in cannot be considered to involve an inventory steel and the constance of particular relevance; the claimed involve an inventory steel and the protein of the common to considered to involve an inventory steel and the constance of particular relevance; the claimed involve an inventory steel and the particular relevance; the claimed involve an inventory steel and the protein of the common to considered to involve an inventory steel and the protein of t]	H3	V-1 VER Protein recog	Mized pi	1
different HLA-R molecules", pages 2383-2386, see entire document. The Journal of Experimental Medicine, Volume 170, issued December 1989. Takahashi et al. "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immuno- deficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. *Special categories of cated decuments: " "A" decument determinant of the art which is not cannot be described as the structure relevance of the cannot be considered in which may five decument structure and interest the claimed in cannot be considered to investe an investe an investe an investe structure relevance; the claimed investe an investe a		cz.t	otoxic I limbuocites	or seropositive	<u> </u>
The Journal of Experimental Medicine, Volume 170, issued December 1989. Takahashi et al. "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immuno- deficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. *Secul categories of cool documents: " "A decument defining the general state of the art which is not considered to be of surfacular relevance or greatly date and not in confict with the application considered to be of surfacular relevance or greatly date and not in confict with the application of the date of the confidence of the confidence of the result of the state of the s]	inc	lividuals in associati	on with	
The Journal of Experimental Medicine, Volume 170, issued December 1989. Takahashi et al. "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immuno- deficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. *Special categories of cased documents: " "A" decument defining the general state of the art which is not cansidered to be of surfacials relevance "T" decument defining the general state of the art which is not cansidered to be of surfacials relevance "T" decument but published on or after the international films of the content which may fix be desired. How details of another critation of other means "T" decument referring to an eral disclosure, use, exhibition or other means "T" decument referring to an eral disclosure, use, exhibition or other means "T" decument referring to an eral disclosure, use, exhibition or other means "T" decument referring to an eral disclosure, use, exhibition or other means "T" decument published grey to the international films decument is combined with one or more other such means. Such combination being obvious to a person in the art.		dif	terent HTV-R morecore	s", pages	İ
Tolume 170, issued December 1989. Takahashi et al. "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunodminant determinant of the human immunodeficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. * Special categories of cated documents: "	1	238	13-2386, see entire do	cument.	Ì
Tolume 170, issued December 1989. Takahashi et al. "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunodminant determinant of the human immunodeficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. *Special categories of cited documents: " "A" decument defining the general state of the art which is not consupered to be of particular relevance in the antiferior of consupered to be of particular relevance in the antiferior of cited to endorstand the particular relevance; the claimed in cannot be consudered to meet the consultation of other means in the antiferior of document referring to an eral disclosure, use, exhibition or other means "P" decument published prior to the international filing date but	}				1-26
Takahashi et al. "Structure Requirements for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunodminant determinant of the human immunodeficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. * Special categorys of cated documents: " "A" document defining the general state of the art which is not considered to the of surfacial relevance the set surface and not in confict with the application of cated document but published on or after the international film of contents document which may throw doubts on prorter claimed or cannot be considered to involve an inventive sites of document referring to an oral disclosure, use, echibition or other means. """ document referring to an oral disclosure, use, echibition or other means. """ document referring to an oral disclosure, use, echibition or other means. """ document referring to an oral disclosure, use, echibition or other means. """ document referring to an oral disclosure, use, echibition or other means. """ document referring to an oral disclosure, use, echibition or other means. """ document referring to an oral disclosure, use, echibition or other means. """ document referring to an oral disclosure, use, echibition or other means. """ document referring to an oral disclosure, use, echibition or other means. """ document referring to an oral disclosure, use, echibition or other means. """ document referring to an oral disclosure, use, echibition or other means.	TP	Th€	Journal of Experimen	ital Nedicine,	1-20
for class I MHC Molecule-medicated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immuno- deficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. "Special categories of cased documents: " "A" decument defining the general state of the art which is not cansidered to be of surfacials relevance to the after the international films of any decument but published on or after the international films decument which may fively debuts on property claims or which is crime to establish the debuts of another cristment or other section or other section and disclosure, use, exhibition or other means. """ decument referring to an eral disclosure, use, exhibition or other means. """ decument referring to an eral disclosure, use, exhibition or other means. """ decument published grey to the international filing date but	***	(0)	ume 170, issued Decem	iber 1989.	
antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immuno- deficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. "Special categories of cated documents: " "A" decument defining the general state of the art which is not cansidered to be of surficial relevance in the art which is not cansidered to be of surficial relevance in the arternational films of the decument but published on or after the international films of protein decument of particular relevance; the claimed in cannot be considered in medical relevance; the claimed in cannot be considered to involve an inventive site and other means. "" decument referring to an eral disclosure, use, exhibition or other means. "" decument referring to an eral disclosure, use, exhibition or other means. "" decument published grier to the international filing date but	ì	Tak	ahashi et al. "Struct	ure Keduliements	
T cell recognition of an immunodominant determinant of the human immuno-deficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. * Special categories of cited documents: ** "A" document defining the general state of the art which is not considered to be of surfacials relevance "E" deter document but published on or after the international film or greated date and not in conflict with the application from the published on or after the international film or greated to understand the principle of the international film or greated to understand the principle of understand the principle of understand the cannot be considered in an eventual relevance; the claimed international relevance to the international film or greated an international film or greated an international film or greated and not in conflict with the application of the international film or greated to understand the international film or gr	ŀ	for	class I MMC Molecule	-medicated	
deficiency virus envelope protein", pages 2023-2035, especially pages 2023 & 2026. "Special categories of cited documents: " "A" document defining the general state of the art which is not considered to be of surficials relevance "E" described document but published on er after the international films date "I" decriment which may throw doubts on progret claims) or which is crite to established into date of another citation or other special reason (as specified) "O" document referring to an eral disclosure, use, exhibition or other means. "P" document published arror to the international films date but	- 1	ant	igen presentation and	cytotoxic	
deficiency virus envelope protein*, pages 2023-2035, especially pages 2023 & 2026. "Special categories of cited documents: 18 "A" document defining the general state of the art which is not considered to the of strictular relevance in the property claims of the envelope of the organization of the organization of the envelope of the	1	TC	cell recognition of an	immunodominant	
* Special categories of cited documents: ** "A" document defining the general state of the art which is not considered to be of particular relevance of the art which is not considered to be a particular relevance of the art which is not considered to be a particular relevance of the art which is not considered to be a particular relevance of the art which is critical to understand the principle or theiry underly which gate "C" document which may throw doubts on priority claim(s) or which is critical to relevance in the cannot be considered novel or cannot be considered to involve an inventive size of the involve an inventive and involve an inventive and involve an inventive size of the involve and involve an inventive and involve an inventive and involve an inventive size of the international file of another considered to involve an inventive and involve an inventive size of the international file. """ document relevance: the claimed involve an inventive size of the international file. """ document relevance of particular relevance: the claimed involve an inventive size of the international file. """ document relevance of particular relevance: the claimed involve an inventive size of the international file. """ document relevance of particular relevance: the claimed involve an inventive size of the international file. """ """ document relevance of particular relevance; the claimed involve an inventive size of the international file. """ """ document relevance of particular relevance; the claimed involve an inventive size of the inventive and inventive and inventive an inventive size of the inventive and inventive an	1	đet	erminant of the human	1 mmuno-	ł
* Special categorys of cited documents: ** "A" document defining the general state of the art which is not considered to the personal state of the art which is not considered to the personal relevance or arrivation. "E" decrement but published on or after the international filting date. "L" decrement but published on or after the international filting date. "C" decrement which may throw doubts on pright claim(s) or which is critic to establish the data of another claim(s) or which is critic to establish the data of another claim(s) or which is critic to establish the person (as specified). "O" document referring to an eral disclosure, use, exhibition or other means. "P" document published prior to the international filting date but	1	def	iciency virus envelop	e protein", pages	į (
"A" decument defining the general state of the art which is not consupered to be of particular relevance "E" earlier document but published on or after the international filing date "L" decument which may throw doubts on priority claims) or which is crime to establish the bullet, when date of another crashed or orbits sectal reason has special reason and the particular relevance; the claimed on the reason of particular relevances; the relevances of particular relevances; the relevances of particular relevances; the relev	1	202	3-2035, especially pa	ges 2023 & 2026.	1
"A" decument defining the general state of the art which is not considered to be of particular relevance articles and the published on or after the international filing date. "E" decument which mer throw deutots on priority claims) or which is crime to establish the outside of another citation or other special reason (as special reas					
considered to be of particular relevance "E" earlier document but published on or after the international filling date "L" decument which may throw doubts on priority claims) or which is crime to establish the bullet of another crashing or other sectal reason (as sectional another crashing or other sectal reason (as sectional or other sectal reason (as sectional or other means." "O" document referring to an eral disclosure, use, exhibition or other means." "P" document published giver to the international filling date but		•		or energy date and not in confi-	el with the application hu
"E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claims) or which is crime to establish the bullin, from date of another critical or other secular relevance; the claimed involves an inventors state "O" document inferring so an eral disclosure, use, exhibition or other means "P" document published prior to the international hing date but	COMSK	dered to be	of particular relevance	cited to understand the principle invention	s or theory underlying the
"I" decument which may firm doubts on priority claimids) or which is crime to establish the solution and also of another cristion or other sectal reason (as special	"E" cortice	decument	but published on or after the international	"Y" document of particular relevant	te: the claimed invention
"O" document information and discontinuous exhibition of amother of exhibition or other means. "O" document reference; the claimed incommend the commend an inventive size an order means. "P" document published prior to the international fring date but	"L" docum	nent which	mer throw doubts on priority claims) or	involve an inventive stee	
"O" document referring to an eral disclosure, use, echibition or other means. Such combination being obvious to a person in the art. "P" document published prior to the international filing date but	which	15 CH-6 14	rentons to each north-value ent mateuare	"Y" document of particular relevant	se; the claimed investige
other means ments, such computation some assess to a person in the art. "P" document published grier to the international filing date but	"O" decun	nent referr		decument is combined with one	or more other such ducy
	other	means	•		
later than the errority date claimed "A" deciment member of the same parent tamely				"A" document member of the same (patent family
V. CERTIFICATION	V. CERTIS	ICATION		-	
			pirton of the International Search	Date of Maring of the International Se	arch Report
2.2 FFR 4004	_			22FFB 1	001
06 February 1991 ** ** FED [39]	06 F	ebruai	J 1731	~~LFD !	221
mornaumal Searcturing Authority Signature of Authorited Office for	meraneal	Searclung	Authority		
ISA/US Lynette F. Smith ebw	ISA/	ับร		Lynette F. Smith	ebv

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET				
v. Observations where certain claims were found unsearchable 1				
This international search report has not been established in respect of certain claims under Article 17(2) (a) for	•			
1. Claim numbers , because they relate to subject matter 12 not required to be searched by this Auth	verity, namely:			
•				
2. Claim numbers , because they relate to parts of the international application that do not comply we	th the prescribed require-			
ments to such an extent that no meaningful international search can be carried out 12, specifically:				
•				
	•			
1. Claim numbers because they are dependent claims not dratted in accordance with the second and third sentences of				
PCT Rule 6.4(a).				
VL区 ORSERYATIONS WHERE UNITY OF INVENTION IS LACKING I				
This international Secretary Authority found multiple inventions in this international application as follows: I. Claims 1-6,17-22 to peptide fragments and use thereof	•			
II. Claims 7-10 to GAG peptide fragment				
III. Claims 11-16 to envelope protein pentide framents.				
IV. Claims 23-26 to in vivo administration of HEF protein				
1. As all required additional search fees were itsely paid by the socileant, this international search report co- of the informations sealication.	vers all searchable claims			
2. As only some of the required additional search fees were timely said by the applicant, this international search report covers only				
these claims of the international application for which fees were paid, specifically claims:				
3. No recoved additional search less were timely said by the ensircant. Consequently, this international sear the invention tirst mentioned in the claims; it is covered by claim numbers:	rch report is restricted to			
4 As all searchable claims could be searched without effort justifying an additional lies, the international be				
nime payment of any additional fre.				
Remark on Protest The additional search lives were accompanied by applicant's protest.				
Rio protest accompanied the payment of additional search fees.				

Form FCT/SA/210 (Incomments about 69 (Page, 11-87)